Progress in Imaging Diagnosis and Image-guided Puncture Biopsy of Prostate Cancer

doi:10.37015/AUDT.2019.191223

Abstract

Abstract:

The current standard technique for diagnosing prostate cancer (PCa) in men at risk relies on a transrectal ultrasound (TRUS)-guided needle biopsy due to its real-time nature and simplicity to obtain systematic histological specimens of the prostate. Also several magnetic resonance imaging (MRI)-based techniques have been employed due to their high detection rate of clinically significant PCa (csPCa). MRI-TRUS fusion imaging contains both the information of MRI and TRUS images for prostate biopsies. This technique combines the strengths of these two techniques, including the superior sensitivity of MRI for targeting cancerous lesions the real time and practicality of TRUS. This review briefly introduces the development of TRUSguided biopsy, MRI-guided biopsy and MRI-TRUS fusion imaging techniques for prostate cancer.

Key words: Ultrasound; Image-guided biopsy; Magnetic Resonance Imaging; Prostate cancer

Lixue Zhai, MD, Xiaojuan Zhang, MD, Yuxiu Gao, MD, Zhaoyan Ding, MD, Haiyang Yu, MD, Cheng Zhao, MD. Progress in Imaging Diagnosis and Image-guided Puncture Biopsy of Prostate Cancer. Advanced Ultrasound in Diagnosis and Therapy, 2019, 3(4): 175-181.

References

[1]	Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 2019: JCO1901638.
[2]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69:7-34.
[3]	Thompson JE, Moses D, Shnier R, Brenner P, Delprado W, Ponsky L, et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol 2014; 192:67-74.
[4]	Goldberg H, Ahmad AE, Chandrasekar T, Klotz L, Emberton M, Haider MA, et al. Comparison of MRI- and TRUS-informed prostate biopsy for prostate cancer diagnosis in biopsy-naive men: A systematic review and Meta-analysis. J Urol 2019: 101097JU0000000000000595.
[5]	Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71:618-29.
[6]	Lee HY, Lee HJ, Byun SS, Lee SE, Hong SK, Kim SH. Classification of focal prostatic lesions on transrectal ultrasound (TRUS) and the accuracy of TRUS to diagnose prostate cancer. Korean J Radiol 2009; 10:244-51.
[7]	Brock M, von Bodman C, Sommerer F, L?ppenberg B, Klein T, Deix T, et al. Comparison of real-time elastography with grey-scale ultrasonography for detection of organ-confined prostate cancer and extra capsular extension: a prospective analysis using whole mount sections after radical prostatectomy. BJU Int 2011; 108:E217-22.
[8]	Shoji S. Magnetic resonance imaging-transrectal ultrasound fusion image-guided prostate biopsy: Current status of the cancer detection and the prospects of tailor-made medicine of the prostate cancer. Investig Clin Urol 2019; 60:4-13.
[9]	Toi A, Neill MG, Lockwood GA, Sweet JM, Tammsalu LA, Fleshner NE. The continuing importance of transrectal ultrasound identification of prostatic lesions. J Urol 2007; 177:516-20.
[10]	Hodge KK, McNeal JE, Stamey TA. Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 1989; 142:66-70.
[11]	Penzkofer T, Tempany-Afdhal CM. Prostate cancer detection and diagnosis: the role of MR and its comparison with other diagnostic modalities--a radiologist's perspective. NMR Biomed 2014; 27:3-15.
[12]	Bansal S, Gupta NP, Yadav R, Khera R, Ahlawat K, Gautam D, et al. Multiparametric magnetic resonance imaging-transrectal ultrasound fusion prostate biopsy: A prospective, single centre study. Indian J Urol 2017; 33:134-139.
[13]	Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, et al. Prostate magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a prior negative biopsy: a consensus statement by AUA and SAR. J Urol 2016; 196:1613-1618.
[14]	Mitterberger MJ, Aigner F, Horninger W, Ulmer H, Cavuto S, Halpern EJ, et al. Comparative efficiency of contrast-enhanced colour Doppler ultrasound targeted versus systematic biopsy for prostate cancer detection. Eur Radiol 2010; 20:2791-6.
[15]	Jelidi A, Ohana M, Labani A, Alemann G, Lang H, Roy C. Prostate cancer diagnosis: Efficacy of a simple electromagnetic MRI-TRUS fusion method to target biopsies. Eur J Radiol 2017; 86:127-134.
[16]	Saba K, Wettstein MS, Lieger L, H?tker AM, Donati OF, Moch H, et al. External validation and comparison of prostate cancer risk calculators incorporating multiparametric magnetic resonance imaging for prediction of clinically significant prostate cancer. J Urol 2019: 101097JU0000000000000622.
[17]	Zhang F, Liu CL, Chen Q, Shao SC, Chen SQ. Accuracy of multiparametric magnetic resonance imaging for detecting extracapsular extension in prostate cancer: a systematic review and meta-analysis. Br J Radiol 2019; 92:20190480.
[18]	Sonn GA, Natarajan S, Margolis DJ, MacAiran M, Lieu P, Huang J, et al. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol 2013; 189:86-91.
[19]	Wegelin O, van Melick HHE, Hooft L, Bosch JLHR, Reitsma HB, Barentsz JO, et al. Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. Is there a preferred technique? Eur Urol 2017; 71:517-531.
[20]	Nyarangi-Dix J, Wiesenfarth M, Bonekamp D, Hitthaler B, Schütz V, Dieffenbacher S, et al. Combined clinical parameters and multiparametric magnetic resonance imaging for the prediction of extraprostatic disease-a risk model for patient-tailored risk stratification when planning radical prostatectomy. Eur Urol Focus 2018; S2405-4569(18) 30336-5.
[21]	Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2005; 62:140-7.
[22]	Gibbs P, Liney GP, Pickles MD, Zelhof B, Rodrigues G, Turnbull LW. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol 2009; 44:572-6.
[23]	Di Campli E, Delli Pizzi A, Seccia B, Cianci R, d'Annibale M, Colasante A , et al. Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: Comparison between readers with different experience. Eur J Radiol 2018; 101:17-23.
[24]	Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Fütterer JJ, Gill IS, et al. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol 2013; 64:544-52.
[25]	Park BK, Park JW, Park SY, Kim CK, Lee HM, Jeon SS, et al. Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. AJR Am J Roentgenol 2011; 197:W876-81.
[26]	Skorpil M, Brynolfsson P, Engstr?m M. Motion corrected DWI with integrated T2-mapping for simultaneous estimation of ADC, T2-relaxation and perfusion in prostate cancer. Magn Reson Imaging 2017; 39:162-167.
[27]	Barret E, Turkbey B, Puech P, Durand M, Panebianco V, Fütterer JJ, et al. Update on the ICUD-SIU consultation on multi-parametric magnetic resonance imaging in localised prostate cancer. World J Urol 2019; 37:429-436.
[28]	Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011; 59:477-94.
[29]	Kobus T, Hambrock T, Hulsbergen-van de Kaa CA, Wright AJ, Barentsz JO, Heerschap A, et al. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil. Eur Urol 2011; 60:1074-80.
[30]	John S, Cooper S, Breau RH, Flood TA, Cagiannos I, Lavallee LT, et al. Multiparametric magnetic resonance imaging - Transrectal ultrasound-guided cognitive fusion biopsy of the prostate: Clinically significant cancer detection rates stratified by the Prostate Imaging and Data Reporting System version 2 assessment category. Can Urol Assoc J 2018.
[31]	Hegde JV, Mulkern RV, Panych LP, Fennessy FM, Fedorov A, Maier SE, et al. Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging 2013; 37:1035-54.
[32]	Ferda J, Kastner J, Hora M, Hes O, Fínek J, Topol?an O, et al. A role of multifactorial evaluation of prostatic 3T MRI in patients with elevated prostatic-specific antigen levels: prospective comparison with ultrasound-guided transrectal biopsy. Anticancer Res 2013; 33:2791-5.
[33]	Kaplan I, Oldenburg NE, Meskell P, Blake M, Church P, Holupka EJ. Real time MRI-ultrasound image guided stereotactic prostate biopsy. Magn Reson Imaging 2002; 20:295-9.
[34]	Cash H, Maxeiner A, Stephan C, Fischer T, Durmus T, Holzmann J, et al. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy. World J Urol 2016; 34:525-32.
[35]	Ukimura O, Marien A, Palmer S, Villers A, Aron M, de Castro Abreu AL , et al. Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies. World J Urol 2015; 33:1669-76.
[36]	Xu S, Kruecker J, Turkbey B, Glossop N, Singh AK, Choyke P, Pinto P, Wood BJ. Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg 2008; 13:255-64.
[37]	Todenh?fer T, Hennenlotter J, Keller G, Neumann T, Stenzl A, Bedke J. Effect of radical prostatectomy on levels of cancer related epitopes in circulating macrophages of patients with clinically localized prostate cancer. Prostate 2017; 77:1251-1258.
[38]	Chamie K, Sonn GA, Finley DS, Tan N, Margolis DJ, Raman SS, et al. The role of magnetic resonance imaging in delineating clinically significant prostate cancer. Urology 2014; 83:369-75.
[39]	Delongchamps NB, Peyromaure M, Schull A, Beuvon F, Bouazza N, Flam T, et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. J Urol 2013; 189:493-9.
[40]	Logan JK, Rais-Bahrami S, Turkbey B, Gomella A, Amalou H, Choyke PL, et al. Current status of magnetic resonance imaging (MRI) and ultrasonography fusion software platforms for guidance of prostate biopsies. BJU Int 2014; 114:641-52.